Oxaliplatin Medac (Oxaliplatin)

Oxaliplatin is a platinum‑based agent used in the treatment of cancers that respond to DNA‑damaging chemotherapy.

• Colorectal cancer: Improves survival and reduces tumour size in adjuvant and metastatic settings.
• Gastric cancer: Used in combination regimens to enhance response rates.
• Pancreatic cancer: Contributes to tumour control when combined with other cytotoxics.
• Ovarian cancer: Added to standard regimens for improved disease control.
• Esophageal cancer: Utilised in multi‑drug protocols for tumour reduction.
• Small‑cell lung cancer: Employed as part of combination therapy to increase response.

• Oxaliplatin exerts its anticancer effect by forming platinum‑DNA adducts that distort the DNA helix, inhibiting replication and transcription. The resulting DNA cross‑links trigger cell‑cycle arrest and apoptosis, particularly in rapidly dividing tumor cells. Its activity is enhanced in the presence of intracellular copper transport mechanisms that facilitate drug uptake.

Oxaliplatin may elicit a range of adverse reactions, from mild to severe, depending on individual tolerance and treatment context.

Common Side Effects

• Nausea and vomiting: Frequently reported during and after infusion.
• Peripheral neuropathy: Tingling or numbness, often dose‑dependent.
• Diarrhoea: May occur during treatment cycles.
• Fatigue: Generalised tiredness common in chemotherapy.
• Thrombocytopenia: Reduced platelet counts observed in labs.
• Elevated liver enzymes: Mild transaminase rise detectable in blood tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: Anaphylaxis or bronchospasm during infusion.
• Acute hemolytic anemia: Rapid destruction of red blood cells.
• Severe neutropenia: Marked drop in neutrophil count increasing infection risk.
• Cardiotoxicity: Rare cardiac dysfunction or arrhythmia.
• Pulmonary toxicity: Interstitial lung disease or pneumonitis.
• Renal failure: Acute kidney injury in susceptible patients.

When handling Oxaliplatin Medac, clinicians should observe specific safety measures and patient monitoring protocols.

• Renal function assessment: Baseline and periodic creatinine testing recommended.
• Hepatic function monitoring: Liver enzymes should be checked before each cycle.
• Neuropathy surveillance: Evaluate sensory changes before and during therapy.
• Hematologic monitoring: CBC with differential prior to each infusion.
• Pregnancy and lactation warning: Contra‑indicated unless benefits outweigh risks.
• Store at ambient temperature: Keep vials in original packaging, protect from light and moisture.

Oxaliplatin can interact with several concomitant medications, altering its efficacy or toxicity profile.

Major Interactions (Avoid)

• Aminoglycoside antibiotics: May increase nephrotoxic risk.
• High‑dose vitamin C: Potentially reduces platinum‑DNA binding.
• Concomitant platinum agents: Cumulative toxicity concerns.

Moderate Interactions (Monitor Closely)

• Antiemetics 5‑HT3 antagonists: May affect infusion‑related nausea control.
• Loop diuretics: Require renal function monitoring.
• Anticoagulants: Increased bleeding risk with thrombocytopenia.